Clinical Evidence: What UK Trials Reveal About Each Treatment
Why Mounjaro's Dual-Action May Appeal Over Wegovy's Single Pathway
The fundamental difference in why some patients and prescribers consider Mounjaro potentially superior to Wegovy lies in their distinct mechanisms of action. Mounjaro (tirzepatide) functions as a dual agonist, targeting both GIP and GLP-1 receptors simultaneously, whilst Wegovy (semaglutide) works exclusively through GLP-1 receptor activation. This dual-action approach may provide enhanced metabolic benefits beyond appetite suppression alone.
Clinical research suggests that GIP receptor activation may complement GLP-1 effects by improving insulin sensitivity and glucose metabolism. However, both remain prescription-only medicines requiring thorough clinical assessment. EverydayMeds provides access to both treatments through our GPhC-registered pharmacy (#9012878), allowing prescribers to determine which mechanism aligns with individual patient profiles. The choice between single and dual-action approaches depends on various factors including medical history and treatment goals.
UK Pricing Comparison: Mounjaro vs Wegovy Value Analysis
When examining why Mounjaro might be preferred over Wegovy, cost considerations play a significant role for UK patients. Wegovy pricing at EverydayMeds starts from £79.99 for the 0.25mg starter dose, with our Intro Duo bundle (0.25mg & 0.5mg) available for £169.99. New customers apply code FIRST40 at checkout, whilst returning patients use DOSE25 for transparent pricing. The maintenance 2.4mg dose costs £209.99, with the Ultimate Stability Trio providing three months' supply for £649.99.
Mounjaro pricing typically differs due to its dual-action formulation and manufacturing complexity. Both treatments require dose escalation protocols, making bundle options particularly valuable for UK patients seeking consistent supply. EverydayMeds offers next-day cold-chain delivery for both medications, ensuring proper temperature control throughout transit. Your prescriber can discuss cost-effectiveness alongside clinical suitability during the assessment process. Bundle pricing provides convenience through reduced ordering frequency rather than pure savings calculations.
Clinical Trial Evidence: Wegovy's STEP Programme vs Mounjaro's SURMOUNT Studies
Understanding why some consider Mounjaro superior to Wegovy requires examining their distinct clinical trial programmes. Wegovy's evidence comes primarily from the STEP trials, where patients taking semaglutide alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks in STEP 1 (Wilding et al., NEJM, 2021). The STEP 5 study demonstrated sustained weight loss of around 15.2% at two years, whilst SELECT showed 20% cardiovascular risk reduction.
Mounjaro's SURMOUNT trials evaluated tirzepatide's dual-action approach in similar populations, though direct comparison remains challenging due to different trial designs and endpoints. Both programmes required participants to follow reduced-calorie diets with increased physical activity. Individual responses vary significantly, and past trial performance doesn't assurance future individual results. Both medications are available from EverydayMeds following appropriate clinical assessment and prescriber approval.
How Wegovy Works: Understanding GLP-1 Receptor Mechanisms
Wegovy functions as a GLP-1 receptor agonist, mimicking natural incretin hormones that regulate appetite and glucose metabolism. The medication binds to GLP-1 receptors in the brain's appetite control centres, promoting feelings of fullness and reducing food cravings between meals. This mechanism slows gastric emptying, meaning food remains in the stomach longer, contributing to sustained satiety signals. Wegovy's once-weekly injection provides consistent hormone level maintenance throughout the dosing period. The treatment works best when combined with lifestyle modifications including reduced-calorie diets and regular physical activity. Clinical studies suggest this approach may help patients develop healthier eating patterns over time.
EverydayMeds Ordering Process: From Assessment to Delivery
Accessing either Wegovy or Mounjaro through EverydayMeds begins with our comprehensive three-minute online clinical assessment, covering medical history, current medications, and weight management goals. Our prescribers review submissions within standard three working days, with express 24-hour review available for urgent requirements. Once approved, medications are dispatched via next-day delivery using specialist cold-chain logistics to maintain proper temperature throughout transit. All shipments include temperature monitoring devices and insulated packaging designed for UK climate conditions. Our GPhC-registered pharmacy (#9012878) ensures full regulatory compliance and pharmaceutical standards. Patient support continues throughout treatment with access to clinical guidance and dosing advice.
Storage and Practical Considerations: Wegovy vs Mounjaro Convenience
When considering why Wegovy might be preferred over Mounjaro for practical reasons, storage flexibility represents a key advantage. Wegovy pens maintain stability for six weeks at room temperature below 30°C once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. Both require refrigeration at 2-8°C before first use and utilise similar injection pen technology for patient convenience. Wegovy's FlexTouch pen design provides consistent dosing accuracy with built-in safety features to prevent accidental injection. The longer room temperature stability makes Wegovy particularly suitable for patients who travel frequently or have limited refrigeration access. Both medications follow mandatory dose escalation schedules that cannot be skipped or accelerated without prescriber guidance.
UK-Specific Weight Management Considerations: NICE Guidelines and NHS Context
The debate over why Mounjaro might be considered superior to Wegovy must acknowledge UK-specific prescribing contexts and NICE guidance. Both medications are recommended under specific BMI and comorbidity criteria, with NICE TA875 supporting Wegovy use alongside specialist weight management programmes. NHS availability remains limited, making private options like EverydayMeds essential for patient access. UK prescribers consider individual patient factors including diabetes status, cardiovascular risk, and previous treatment responses when choosing between single and dual-action approaches.
EverydayMeds operates within UK pharmaceutical regulations, ensuring both treatments meet MHRA standards for quality and safety. Our clinical assessment process aligns with UK prescribing guidelines whilst providing convenient access outside traditional NHS pathways. The choice between Mounjaro's dual-action mechanism and Wegovy's established GLP-1 approach depends on individual clinical pictures rather than universal superiority. Both remain prescription-only medicines requiring ongoing medical supervision and lifestyle modification commitment.
Making Your Decision: Expert Guidance and Next Steps
Determining whether Mounjaro represents a better choice than Wegovy requires personalised clinical assessment considering your medical history, treatment goals, and individual circumstances. EverydayMeds prescribers evaluate multiple factors including current medications, comorbidities, and previous weight management attempts to recommend the most appropriate option. Our transparent pricing structure with codes FIRST40 for new customers and DOSE25 for returning patients ensures clarity throughout the process. Both treatments are available with next-day delivery and ongoing clinical support throughout your weight management journey. Visit https://everydaymeds.co.uk/collections/wegovy to begin your clinical assessment and access expert guidance on choosing between these evidence-based treatment options. Remember that sustainable weight management requires long-term commitment to both medication adherence and lifestyle modifications for optimal results.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
